Exelixis | EXEL - Assets

Exelixis reported $3.07B in Assets for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Assets Change
Acadia Pharmaceuticals ACAD:US USD 587.81M 14.68M
Agios Pharmaceuticals AGIO:US USD 1.24B 58.4M
Akebia Therapeutics AKBA:US USD 351.83M 84.06M
Amgen AMGN:US USD 65.12B 1.42B
AstraZeneca AZN:LN USD 96.48B 2.3B
Bayer BAYN:GR EUR 124.88B 6.13B
Biomarin Pharmaceutical BMRN:US USD 6.38B 111.03M
Bluebird Bio BLUE:US USD 520.1M 53.49M
Cytokinetics CYTK:US USD 1.01B 61.19M
Eisai 4523:JP JPY 1.25T 10.21B
Esperion Therapeutics ESPR:US USD 247.94M 64.89M
Exelixis EXEL:US USD 3.07B 110.12M
Genmab GEN:DC DKK 30.28B 408M
Glaxosmithkline GSK:US GBP 60.15B 167M
Immunogen IMGN:US USD 348.94M 9.86M
IONIS PHARMACEUT IONS:US USD 2.53B 111.9M
Macrogenics MGNX:US USD 280.47M 85.12M
Mirati Therapeutics MRTX:US USD 1.2B 100.44M
Moderna Inc MRNA:US USD 25.86B 198M
Nektar Therapeutics NKTR:US USD 710.6M 70.41M
Neurocrine Biosciences NBIX:US USD 2.37B 225.3M
Novartis NOVN:VX USD 117.45B 1.01B
Puma Biotechnology PBYI:US USD 222.06M 23.29M
Seattle Genetics SGEN:US USD 3.67B 55.45M
Takeda 4502:JP JPY 13.5T 1.08T
Ultragenyx Pharmaceutical RARE:US USD 1.55B 73.03M
Xencor XNCR:US USD 846.27M 11M
YTE INCY:US USD 5.84B 330.77M